Clusters of Disease Activity and Early Risk Factors of Clinical Course of Pediatric Crohn's Disease.

Crohn’s disease children cluster prognostic risk factors

Journal

Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162

Informations de publication

Date de publication:
23 Nov 2023
Historique:
received: 24 05 2023
medline: 24 11 2023
pubmed: 24 11 2023
entrez: 23 11 2023
Statut: aheadofprint

Résumé

This study aimed to define clusters of disease activity and prognostic factors of disease course in a well-characterized cohort of children with Crohn's disease (CD). All patients from the SIGENP IBD (Italian Society of Pediatric Gastroenterology Hepatology and Nutrition Inflammatory Bowel Disease) registry with a 5-year follow-up and 6-monthly evaluation were included. Active disease was defined for each semester as follows: clinical activity (weighted Pediatric Crohn's Disease Activity Index ≥12.5 or Mucosal Inflammation Noninvasive Index ≥8) and active disease on endoscopy (Simple Endoscopic Score for Crohn's Disease >3 or fecal calprotectin >250 µg/g) or imaging. Formula-based clusters were generated based on previously published patterns in adults. Data from 332 patients were analyzed. A total of 105 (32%) experienced a quiescent disease course; 49 (15%) and 31 (9%) a moderate-to-severe chronically active and chronic intermittent disease, respectively; 104 (31%) and 43 (13%) had active disease in the first 2 years after diagnosis and remission thereafter and vice versa, respectively. Surgery at diagnosis was significantly associated with a quiescent course (odds ratio [OR], 10.05; 95% confidence interval [CI], 3.05-25.22; P=.0005), while growth impairment at the diagnosis and active disease requiring corticosteroids at 6 months were inversely related to the quiescent group (OR, 0.48; 95% CI, 0.27-0.81; P= .007; and OR, 0.35; 95% CI, 0.16-0.71; P= .005, respectively). Perianal involvement at diagnosis and moderate-severe activity at 6 months correlated with disease progression (OR, 3.85; 95% CI, 1.20-12.85; P=.02). During the first 5 years of follow-up, one-third of children with CD experience a quiescent course. However, another one-third have a moderate-to-severe disease course. Surgery at the diagnosis is related to a quiescent course, while growth impairment and lack of response to induction therapy correlate with more severe disease activity during follow-up. We aimed to define clusters of disease activity and prognostic factors of disease course in pediatric Crohn’s disease. One-third of patients have a quiescent course; however, half of them have an active disease by the end of the 5-year follow-up.

Sections du résumé

BACKGROUND BACKGROUND
This study aimed to define clusters of disease activity and prognostic factors of disease course in a well-characterized cohort of children with Crohn's disease (CD).
METHODS METHODS
All patients from the SIGENP IBD (Italian Society of Pediatric Gastroenterology Hepatology and Nutrition Inflammatory Bowel Disease) registry with a 5-year follow-up and 6-monthly evaluation were included. Active disease was defined for each semester as follows: clinical activity (weighted Pediatric Crohn's Disease Activity Index ≥12.5 or Mucosal Inflammation Noninvasive Index ≥8) and active disease on endoscopy (Simple Endoscopic Score for Crohn's Disease >3 or fecal calprotectin >250 µg/g) or imaging. Formula-based clusters were generated based on previously published patterns in adults.
RESULTS RESULTS
Data from 332 patients were analyzed. A total of 105 (32%) experienced a quiescent disease course; 49 (15%) and 31 (9%) a moderate-to-severe chronically active and chronic intermittent disease, respectively; 104 (31%) and 43 (13%) had active disease in the first 2 years after diagnosis and remission thereafter and vice versa, respectively. Surgery at diagnosis was significantly associated with a quiescent course (odds ratio [OR], 10.05; 95% confidence interval [CI], 3.05-25.22; P=.0005), while growth impairment at the diagnosis and active disease requiring corticosteroids at 6 months were inversely related to the quiescent group (OR, 0.48; 95% CI, 0.27-0.81; P= .007; and OR, 0.35; 95% CI, 0.16-0.71; P= .005, respectively). Perianal involvement at diagnosis and moderate-severe activity at 6 months correlated with disease progression (OR, 3.85; 95% CI, 1.20-12.85; P=.02).
CONCLUSIONS CONCLUSIONS
During the first 5 years of follow-up, one-third of children with CD experience a quiescent course. However, another one-third have a moderate-to-severe disease course. Surgery at the diagnosis is related to a quiescent course, while growth impairment and lack of response to induction therapy correlate with more severe disease activity during follow-up.
We aimed to define clusters of disease activity and prognostic factors of disease course in pediatric Crohn’s disease. One-third of patients have a quiescent course; however, half of them have an active disease by the end of the 5-year follow-up.

Autres résumés

Type: plain-language-summary (eng)
We aimed to define clusters of disease activity and prognostic factors of disease course in pediatric Crohn’s disease. One-third of patients have a quiescent course; however, half of them have an active disease by the end of the 5-year follow-up.

Identifiants

pubmed: 37995723
pii: 7444933
doi: 10.1093/ibd/izad275
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Investigateurs

M Baldi (M)
C Banzato (C)
G Barera (G)
G Castellucci (G)
M Corpino (M)
R Cozzali (R)
C De Giacomo (C)
P Diaferia (P)
D Dilillo (D)
E Felici (E)
M T Illiceto (MT)
D Knafelz (D)
L Norsa (L)
P M Pavanello (PM)
A Ravelli (A)
V Romagnoli (V)
C Romano (C)
S Salvatore (S)

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Manuela Distante (M)

Pediatric Gastroenterology and Liver Unit, Department of Maternal and Child Health, Umberto I Hospital, Sapienza University of Rome, Rome, Italy.

Silvia Rotulo (S)

Pediatric Gastroenterology and Liver Unit, Department of Maternal and Child Health, Umberto I Hospital, Sapienza University of Rome, Rome, Italy.

Marco Ranalli (M)

Pediatric Gastroenterology and Liver Unit, Department of Maternal and Child Health, Umberto I Hospital, Sapienza University of Rome, Rome, Italy.

Eugenio Pedace (E)

Pediatric Gastroenterology and Liver Unit, Department of Maternal and Child Health, Umberto I Hospital, Sapienza University of Rome, Rome, Italy.

Paolo Lionetti (P)

Unit of Gastroenterology and Nutrition, Meyer Children's Hospital, Florence, Italy.

Serena Arrigo (S)

Gastroenterologia ed Endoscopia Pediatrica, IRCCS Istituto Giannina Gaslini, Genoa, Italy.

Patrizia Alvisi (P)

Pediatric Gastroenterology Unit, Maggiore Hospital, Bologna, Italy.

Erasmo Miele (E)

Department of Translational Medical Science, Section of Pediatrics, University of Naples Federico II, Naples, Italy.

Massimo Martinelli (M)

Department of Translational Medical Science, Section of Pediatrics, University of Naples Federico II, Naples, Italy.

Giovanna Zuin (G)

Pediatrics, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.

Matteo Bramuzzo (M)

Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy.

Mara Cananzi (M)

Unit of Gastroenterology, Digestive Endoscopy, Hepatology and Care of Children with Liver Transplantation, University Hospital of Padova, Padova, Italy.

Marina Aloi (M)

Pediatric Gastroenterology and Liver Unit, Department of Maternal and Child Health, Umberto I Hospital, Sapienza University of Rome, Rome, Italy.

Classifications MeSH